Healthcare of Ontario Pension Plan Trust Fund Takes $3.41 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 66,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,412,000.

Other institutional investors have also recently bought and sold shares of the company. Rockefeller Capital Management L.P. raised its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $51,000. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at about $55,000.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $45.61 on Friday. The firm has a market cap of $2.65 billion, a P/E ratio of -89.43, a price-to-earnings-growth ratio of 1.00 and a beta of 0.54. Supernus Pharmaceuticals, Inc. has a 1 year low of $32.83 and a 1 year high of $59.68. The stock has a 50-day simple moving average of $46.34 and a 200-day simple moving average of $49.13.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several research analyst reports. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.